Cross-posted from National Institute of Allergy and Infectious Diseases, NIH

As the National Institutes of Health works to refine its HIV clinical trial networks during a competitive renewal process, all approaches to HIV prevention must be evaluated to determine how they can best contribute to ending the pandemic. To move the needle on the pandemic, new HIV prevention tools must be acceptable to the user, and must offer benefits that outweigh adherence challenges. Developing an array of safe and effective choices that suit individuals – particularly young women – is critical. In a new blog post, Dr. Carl Dieffenbach, Director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, discusses how microbicides can fit into NIH’s clinical HIV prevention research agenda.